Loading...

NovoCure Limited

NVCRNASDAQ
Healthcare
Medical - Instruments & Supplies
$12.04
$-0.50(-3.99%)

NovoCure Limited (NVCR) Company Profile & Overview

Explore NovoCure Limited’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

NovoCure Limited (NVCR) Company Profile & Overview

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

SectorHealthcare
IndustryMedical - Instruments & Supplies
CEOAshley Cordova

Contact Information

44 15 3475 6700
No. 4 The Forum, Saint Helier, JE2 4UF

Company Facts

1,488 Employees
IPO DateOct 1, 2015
CountryJE
Actively Trading

Frequently Asked Questions

;